Cytura Therapeutics B.V.. (3/24/19). "Press Release: Cytura Therapeutics to Develop a New Class of Drugs Targeting Genomic Instability in Cancer".

	Organisation	Cytura Therapeutics B.V.
	Organisation 2	Thuja Capital Healthcare Fund II
	Group	Thuja Capital (Group)
	Product	cancer drug
	Product 2	venture capital
	Index term	Cytura Therapeutics–SEVERAL: investment, 201904 seed financing round led by Thuja Capital Healthcare (Seed) Fund II
	Person	van Gorp, Ad (Cytura Therapeutics 201903– CEO + Co-Founder before Lead Pharma 201502 CEO + Co-founder)

Today Cytura Therapeutics announces the successful closure of a Seed financing round. The funding is provided by a syndicate led by Thuja Capital Healthcare (Seed) Fund II and includes BOM Brabant Ventures, the Centre for Drug Design and Discovery (CD3) – KU Leuven and the Gemma Frisius Fund. Cytura Therapeutics will use the new funding to advance its first proprietary small molecule program and to further expand their pipeline of new disruptive drugs, targeting genomic instability.

Cytura Therapeutics

The company will be based at the Pivot Park Life Science Campus in Oss and collaborate with the Amsterdam UMC and the Centre for Drug Design and Discovery (CD3) of the KU Leuven. Genomic instability is a major problem in cancer progression and therapy resistance. By targeting genome instability this approach could be applied both as a stand-alone as in combinations therapy. On the latter, there is a large group of patients who will at first respond to the applied therapy and later on become resistant during treatment.

“One of the biggest issues in cancer treatment is that the disease has the ability to change its nature over time caused by the increasing genomic instability. Cytura’s R&D efforts are focused on the development of small molecules that will slow down or stop this genomic instability. I am committed to find this medicine which could lead to real advancements in the fight against cancer.”
Ad van Gorp, co-founder of Cytura Therapeutics

Management and shareholders

Cytura Therapeutics is founded by Dr Ad van Gorp, former CEO of Dutch Lead Pharma, the Centre for Drug Design and Discovery (CD3) of the KU Leuven and Amsterdam UMC. In close collaboration with both organizations, Cytura Therapeutics aspires to advance it innovative first-in-class therapies targeting genomic instability of cancers.

Record changed: 2023-06-05

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]